Company / Accounts Receivable
IRONWOOD PHARMACEUTICALS INC Accounts Receivable History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$46.7M
FY2025
5-year range
$46.7M / $129.1M
FY2021-FY2025
Trend
-42.9%
vs FY2024
Sector context
#72 of 115
Health Care
What the data says
At $47M, IRONWOOD PHARMACEUTICALS INC's accounts receivable ranks #72 of 115 in the Health Care sector. Accounts Receivable has fluctuated over the past 10 years, ranging from $933,000 in FY2016 to $129M in FY2023.
Based on SEC 10-K filings.
$47M in FY2025 with a 5-year CAGR of -17.5%.
Declined from $129M to $47M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -26.0%
- 5-Year CAGR
- -17.5%
- 10-Year CAGR
- -
Sector benchmark
#72 of 115 in Health CareTop 63% of 115This company $46.7M Sector average $1.1B
▼
-95.8% below sector average
Key checks
Key Insights
- 5-year CAGR of -17.5%, indicating a declining trend.
- In FY2025, accounts receivable decreased 42.9% year-over-year.
- Ranks #72 out of 115 companies in the Health Care sector.
- Peak accounts receivable was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score -2.17 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $46.7M | -42.9% |
| FY2024 | $81.9M | -36.6% |
| FY2023 | $129.1M | +11.8% |
| FY2022 | $115.5M | +1.2% |
| FY2021 | $114.0M | -6.8% |
| FY2020 | $122.4M | +984.8% |
| FY2019 | $11.3M | -46.3% |
| FY2018 | $21.0M | +558.0% |
| FY2017 | $3.2M | +241.9% |
| FY2016 | $933.0K | -67.6% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026